Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma

Bone Marrow Transplantation

Volumn 46, Issue 4, 2011, Pages 510-515

  Kazmi, S M A ^a   Saliba, R M ^b   Donato, M ^b   Wang, M ^b   Hosing, C ^b   Qureshi, S ^b   Anderlini, P ^b   Popat, U ^b   Champlin, R E ^b   Giralt, S A ^b   Qazilbash, M H ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

autologous stem cell transplant; CY; melphalan; multiple myeloma; topotecan

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; ELECTROLYTE DISTURBANCE; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART EDEMA; HEART FAILURE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; SOCIAL SUPPORT; STEM CELL MOBILIZATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; REMISSION INDUCTION; TOPOTECAN; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79953718494     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.160     Document Type: Article

References (22)

1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N et al. SEER cancer statistics review, 1975-2006. National Cancer Institute: Bethesda, 2008. Available from http://seer.cancer.gov/csr/1975-2006/based on November 2008 SEER data submission, posted to the SEER website, 2009.
2. Attal M, Harousseau JL, Stoppa AM, Sotto KL, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97. (Pubitemid 26240110)
3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883. (Pubitemid 36532313)
4. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936. (Pubitemid 46638847)
5. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755-3759. (Pubitemid 41739009)
6. Conte LG, Figueroa MG, Lois VV, Cabrera CME, Leon RA, Garcia LH et al. Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system. Rev Med Chil 2008; 136: 7-12.
7. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007; 13: 1066-1072. (Pubitemid 47215562)
8. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A et al. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 2006; 47: 1360-1364. (Pubitemid 44269646)
9. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043. (Pubitemid 32591186)
10. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 2010; 45: 498-504.
11. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 rando-mized trial. Blood 2002; 99: 731-735.
12. Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 2005; 130: 588-594. (Pubitemid 43899763)
13. Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001; 27: 821-828. (Pubitemid 32496415)
14. Lahuerta JJ, Grande C, Martinez-Lopez J, De La Serna J, Toscano R, Ortiz MC et al. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos/Trasplante Autologo de Medula Osea phase II trial. Br J Haematol 2003; 120: 296-303. (Pubitemid 36194181)
15. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27: 1788-1793.
16. Kraut EH, Crowley JJ, Wade JL, Laufman LR, Alsina M, Taylor SA et al. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 589-592. (Pubitemid 28135604)
17. Kraut EH, Young D, Farag S, James AG, Solove RJ. Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma. Leuk Res 2005; 29: 1233-1234. (Pubitemid 41169243)
18. Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837-842. (Pubitemid 32496417)
19. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473. (Pubitemid 44264086)
20. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
21. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004; 100: 2607-2612. (Pubitemid 38715766)
22. Benson Jr DM, Elder PJ, Lin TS, Blum W, Penza S, Avalos B et al. High-dose melphalan versus busulfan, cyclophospha-mide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res 2007; 31: 1069-1075.